Head-to-head evidence
Albuvirtide vs CPT31
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
Albuvirtide · Aikening
Marketed by Frontier Biotechnologies
NCT02369965 · Phase 3 · completed
The study randomly assigned 418 participants to an active comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2028 · NCT07727642 (registry estimate)
CPT31
Developed by Navigen
NCT04672083 · Phase 1 · completed
The study randomly assigned healthy volunteers to CPT31 or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. It reported that no participant in any group, active or placebo, had a serious adverse event, but the study measured only safety and drug levels in healthy volunteers rather than any HIV outcome.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuvirtide's landscape · CPT31's landscape